{"url":"https://newsforagent.com/news/2026-10-17/abbvie-ueg-week-crohns-remission-data","markdown_url":"https://newsforagent.com/news/2026-10-17/abbvie-ueg-week-crohns-remission-data.md","title":"AbbVie Reports 86.6% Crohn's Remission at 144 Weeks","headline":"AbbVie Presents 20 IBD Abstracts at UEG Week, Led by 86.6% Crohn's Remission at Week 144","description":"AbbVie presented 20 IBD abstracts at UEG Week 2026, with upadacitinib showing 86.6% clinical remission at week 144 in Crohn's disease.","section":"Research & Clinical Trials","published_at":"2026-10-17T06:28:11+00:00","modified_at":"2026-10-17T06:28:11+00:00","author":"News Desk","key_takeaways":["AbbVie presented 20 new scientific abstracts on its inflammatory bowel disease portfolio at the 2026 UEG Week in Barcelona.","Upadacitinib achieved clinical remission in 86.6% of Crohn's disease patients receiving 30 mg at week 144 in the U-ENDURE analyses.","The real-world UPlift study found 70.2% of 497 evaluable Crohn's disease patients achieved clinical response with upadacitinib within 12 weeks."],"companies":[{"name":"AbbVie","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000r2/abbvie","website":"https://www.abbvie.com"}],"source":{"publisher":"Stock Titan","title":"AbbVie Crohn’s data: 86.6% clinical remission at 144 weeks","url":"https://www.stocktitan.net/news/ABBV/skyrizi-risankizumab-and-rinvoq-upadacitinib-data-highlight-long-x22468a40vss.html"},"other_sources":[],"tags":["Research & Clinical Trials","AbbVie"],"body_markdown":"[AbbVie](https://akta.pro/company-profiles/00000r2/abbvie) presented 20 new scientific abstracts on its inflammatory bowel disease portfolio at the 2026 United European Gastroenterology Week, held October 17-20 in Barcelona, Spain. The data included long-term results showing 86.6% clinical remission at week 144 for upadacitinib in Crohn's disease, according to [Stock Titan](https://www.stocktitan.net/news/ABBV/skyrizi-risankizumab-and-rinvoq-upadacitinib-data-highlight-long-x22468a40vss.html).\n\n## AbbVie's Long-Term Data at UEG Week 2026\n\nThe U-ENDURE as-observed analyses showed clinical and endoscopic outcomes were maintained through approximately four years of treatment. At week 144, clinical remission was achieved by 78.9% of patients receiving 15 mg of upadacitinib and 86.6% receiving 30 mg. Endoscopic remission was achieved by 47.1% and 64.2% of patients, respectively.\n\nIn ulcerative colitis, the COMMAND study showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment with risankizumab. As-observed clinical remission rates of 54.0% to 73.1% and endoscopic remission rates of 38.8% to 53.5% were achieved at week 96 with 180 mg across advanced therapy-naive and advanced therapy-experienced patients.\n\n\"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical,\" said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie.\n\n## AbbVie's Real-World Findings in Crohn's Disease\n\nInterim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical response with upadacitinib within 12 weeks, with a median time to first response of 13 days.\n\nA real-world claims analysis of patients (N=514) with ulcerative colitis or Crohn's disease showed that patients who switched from a Tumor Necrosis Factor inhibitor to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.\n\n## AbbVie's Recent Pipeline and Deal Activity\n\nAbbVie is a global biopharmaceutical company developing and commercializing medicines across immunology, oncology, neuroscience, virology, eye care, and aesthetics, according to [akta.pro company records](https://akta.pro/company-data). The same records show AbbVie announced a definitive agreement in June 2026 to acquire Apogee Therapeutics for approximately $10.9 billion in cash at $135.11 per share, a 49% premium, adding lead asset zumilokibart for atopic dermatitis and APG273 for asthma.\n\nAbbVie's Skyrizi and Rinvoq combined generated $7.29 billion in Q1 2026, up 16% year over year, largely offsetting Humira's 38.6% decline from biosimilar competition, the same records show.\n\n## AbbVie's Earlier IBD and Oncology Milestones\n\nOn October 15, 2026, AbbVie and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL, showing a 51% reduction in disease progression or death versus R-CHOP alone, according to Yahoo.\n\nOn October 13, 2026, AbbVie received FDA Breakthrough Therapy Designations for Temab A in colorectal and lung cancer, alongside new data for Skyrizi, Rinvoq, and obesity candidate ABBV 295, according to Simply Wall St.\n\nOn August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency seeking approval of Skyrizi for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn's disease.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}